Network


Latest external collaboration on country level. Dive into details by clicking on the dots.

Hotspot


Dive into the research topics where Kazumi Hashizume is active.

Publication


Featured researches published by Kazumi Hashizume.


BJUI | 2013

Relationship between overactive bladder and irritable bowel syndrome: a large‐scale internet survey in Japan using the overactive bladder symptom score and Rome III criteria

Seiji Matsumoto; Kazumi Hashizume; Naoki Wada; Jyunichi Hori; Gaku Tamaki; Masafumi Kita; Tatsuya Iwata; Hidehiro Kakizaki

There is known to be an association between overactive bladder (OAB) and irritable bowel syndrome (IBS). The study investigates the association between OAB and IBS using an internet‐based survey in Japan. It is the first to investigate the prevalence and severity of OAB in the general population using the OAB symptom score questionnaire.


International Journal of Impotence Research | 2014

Association of ED with chronic periodontal disease

Seiji Matsumoto; M Matsuda; M Takekawa; M Okada; Kazumi Hashizume; Naoki Wada; Hori J; G Tamaki; Masafumi Kita; Tatsuya Iwata; Hidehiro Kakizaki

To examine the relationship between chronic periodontal disease (CPD) and ED, the interview sheet including the CPD self-checklist (CPD score) and the five-item version of the International Index of Erectile Function (IIEF-5) was distributed to 300 adult men who received a comprehensive dental examination. Statistical analyses were performed by the Spearmans rank correlation coefficient and other methods. Statistical significance was accepted at the level of P<0.05. The interview sheets were collected from 88 men (response rate 29.3%, 50.9±16.6 years old). There was a statistically significant correlation between the CPD score and the presence of ED (P=0.0415). The results in the present study suggest that ED is related to the damage caused by endothelial dysfunction and the systematic inflammatory changes associated with CPD. The present study also suggests that dental health is important as a preventive medicine for ED.


Neurourology and Urodynamics | 2013

Urodynamic effects of dutasteride add‐on therapy to alpha‐adrenergic antagonist for patients with benign prostatic enlargement: Prospective pressure‐flow study

Naoki Wada; Masafumi Kita; Kazumi Hashizume; Seiji Matsumoto; Hidehiro Kakizaki

We prospectively investigated the effect of dutasteride on clinical and urodynamic parameters in patients with benign prostatic enlargement (BPE).


International Journal of Urology | 2013

Effect of intrathecal administration of E‐series prostaglandin 1 receptor antagonist in a cyclophosphamide‐induced cystitis rat model

Naoki Wada; Seiji Matsumoto; Masafumi Kita; Masaki Watanabe; Kazumi Hashizume; Hidehiro Kakizaki

Objectives:  To investigate the effect of intrathecal administration of E‐series prostaglandin 1 antagonist in cyclophosphamide‐induced murine cystitis.


The Aging Male | 2016

Dutasteride improves bone mineral density in male patients with lower urinary tract symptoms and prostatic enlargement: a preliminary study.

Naoki Wada; Kazumi Hashizume; Seiji Matsumoto; Hidehiro Kakizaki

Abstract Introduction: We studied the effect of dutasteride on bone mineral density (BMD) in aging male patients with lower urinary tract symptoms (LUTS) and prostatic enlargement. Methods: We prospectively studied 17 patients with LUTS and prostatic enlargement. Before and 1 year after dutasteride (0.5 mg daily), we assessed International Prostate Symptom Score (IPSS), prostatic volume (PV), serum prostatic-specific antigen (PSA) and testosterone. BMD in the lumbar and femur was measured by DEXA method. Results: Dutasteride significantly reduced PV (from 51 ± 24 to 34 ± 17 ml, p < 0.001) and improved IPSS (from 15.1 ± 9.8 to 11.7 ± 10.3, p < 0.05). Serum PSA was significantly decreased (from 3.2 ± 2.6 to 1.0 ± 0.8 ng/ml, p < 0.001), while serum testosterone “was not changed” significantly. BMD of the lumbar “was not changed” significantly after dutasteride. BMD of the femur was significantly improved (from 0.75 ± 0.14 to 0.82 ± 0.16 g/cm2, p < 0.01). In nine patients whose testosterone was increased after dutasteride, BMD of the lumbar (from 1.18 ± 0.26 to 1.22 ± 0.25 g/cm2, p < 0.05) and femur (from 0.76 ± 0.12 to 0.84 ± 0.16 g/cm2, p < 0.05) was significantly improved. Conclusions: Dutasteride has a potential to improve BMD with elevation of serum testosterone in aging male patients with LUTS and prostatic enlargement.


Luts: Lower Urinary Tract Symptoms | 2016

Urodynamic Efficacy and Safety of Mirabegron Add-on Treatment with Tamsulosin for Japanese Male Patients with Overactive Bladder.

Naoki Wada; Hiromichi Iuchi; Masafumi Kita; Kazumi Hashizume; Seiji Matsumoto; Hidehiro Kakizaki

To investigate urodynamic efficacy and safety of mirabegron add‐on treatment with tamsulosin for Japanese male patients with overactive bladder (OAB).


Luts: Lower Urinary Tract Symptoms | 2015

Improvement of Overactive Bladder Symptoms and Bladder Ischemia with Dutasteride in Patients with Benign Prostatic Enlargement

Naoki Wada; Seiji Matsumoto; Masafumi Kita; Kazumi Hashizume; Hidehiro Kakizaki

To evaluate the correlation of clinical and urodynamic parameters with bladder vascular resistance before and after dutasteride treatment in patients with lower urinary tract symptoms associated with benign prostatic enlargement.


International Journal of Urology | 2014

Decreased urinary nerve growth factor reflects prostatic volume reduction and relief of outlet obstruction in patients with benign prostatic enlargement treated with dutasteride.

Naoki Wada; Seiji Matsumoto; Masafumi Kita; Kazumi Hashizume; Hidehiro Kakizaki

To examine urinary nerve growth factor before and after dutasteride treatment, and to analyze correlations between clinical parameters and change of urinary nerve growth factor in patients with benign prostatic enlargement.


The Journal of Urology | 2015

MP59-05 ANALYSIS OF FACTORS AFFECTING POST-OPERATIVE SPLIT RENAL FUNCTION AFTER PARTIAL NEPHRECTOMY USING R.E.N.A.L. NEPHROMETRY SCORE

Masafumi Kita; Kazumi Hashizume; Masaki Watanabe; Hori J; Naoki Wada; Makoto Azumi; Tatsuya Iwata; Seiji Matsumoto; Hidehiro Kakizaki

RESULTS: 399 physicians completed the survey with 37% and 34% completing urologic oncology and endourology fellowships respectively. Answers to a question about the best oncologic treatment for 4-10cm RCC included: PN and RN are equal (56%), the best treatment is unknown (38%), and PN was inferior to RN (6%). Geographic location was the only predictor of response (p1⁄40.01). In case scenarios, the decision to offer PN rather than RN for a peripheral exophytic mass was influenced by comfort level with partial nephrectomy (p1⁄40.02). Open vs. MIS approach depends on comfort level and fellowship type. Oncology trained surgeons were more likely to offer open PN; OR 1.95, p1⁄40.003 and endourology fellowship graduates being more likely to offer MIS; OR 3.27, p<0.0001. Surgeon perception that they received adequate training in complex PN is predictive of offering PN for a centrally located RCC (p1⁄40.001). Academic practitioners are more likely to offer PN (p1⁄40.03). In addition, those completing training after 2001 are more likely to offer MIS (p1⁄40.02) and respondents who completed an oncology fellowship were more likely to offer PN to unhealthy patients (p1⁄40.03). CONCLUSIONS: Expert opinion about the best treatment for 410cm RCC varies significantly, with 70% of respondents willing to enroll patients in a randomized clinical trial comparing partial to radical nephrectomy in 4-10cm RCC.


Luts: Lower Urinary Tract Symptoms | 2015

Association between Chronic Periodontal Disease and Lower Urinary Tract Symptoms in Both Sexes

Seiji Matsumoto; Mitsuyoshi Matsuda; Masanori Takekawa; Masuhiko Okada; Kazumi Hashizume; Naoki Wada; Hori J; Masafumi Kita; Tatsuya Iwata; Hidehiro Kakizaki

To investigate the relationship between chronic periodontal disease (CPD) and lower urinary tract symptoms (LUTS) in both sexes.

Collaboration


Dive into the Kazumi Hashizume's collaboration.

Top Co-Authors

Avatar

Seiji Matsumoto

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Hidehiro Kakizaki

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Masafumi Kita

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Tatsuya Iwata

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Naoki Wada

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar

Naoki Wada

University of Pittsburgh

View shared research outputs
Top Co-Authors

Avatar

Hori J

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Masaki Watanabe

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Makoto Azumi

Asahikawa Medical University

View shared research outputs
Top Co-Authors

Avatar

Gaku Tamaki

Asahikawa Medical University

View shared research outputs
Researchain Logo
Decentralizing Knowledge